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Purpose
The purpose of this study is to report real life experiences of sorafenib therapy for hepato-
cellular carcinoma (HCC) in Korea, using a subset of data from GIDEON (Global Investigation
of Therapeutic Decisions in HCC and of Its Treatment with Sorafenib; a large, prospective,
observational study).
Materials and Methods
Between January 2009 and April 2012, a total of 497 patients were enrolled from 11 sites
in Korea. Of these, 482 patients were evaluable for safety analyses. Case report forms of
paper or electronic version were used to record safety and efficacy data from all patients.
Results
More patients of Child-Pugh A received sorafenib for > 8 weeks than did patients of Child-
Pugh B (55.5% vs. 34.3%). Child-Pugh score did not appear to influence the starting dose
of sorafenib, and approximately 70% of patients both in Child-Pugh A and B groups received
the recommended initial daily dose of 800 mg (69.0% and 69.5%, respectively). The median
overall survival (OS) and time to progression (TTP) were 8.5 months and 2.5 months. In
Child-Pugh A patients, the median OS and TTP were 10.2 months and 2.5 months. The most
frequent treatment-emergent drug-related adverse event was hand-foot skin reaction
(31.7%), followed by diarrhea (18.0%). The incidence of treatment-emergent adverse events
was similar in both Child-Pugh A (85.4%) and Child-Pugh B (84.8%) patients.
Conclusion
Sorafenib was well tolerated by Korean HCC patients in clinical settings, and the safety pro-
file did not appear to differ by Child-Pugh status. Survival benefit in Korean patients was in
line with that of a previous pivotal phase III trial (SHARP). 
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Introduction
Hepatocellular carcinoma (HCC) represents the fifth most
common cancer worldwide and is known to cause significant
public health problems, particularly in association with
chronic hepatitis B (CHB) or chronic hepatitis C [1]. Based on
available data, more than half of HCC cases and deaths are
estimated to occur in North Eastern Asian areas including
Korea, China, Taiwan, and Japan where viral hepatitis B or
C is highly prevalent [2]. Unlike other solid tumors, HCC
presents several unique characteristics, including multifocal
tumorigenesis, frequent vascular invasion, recurrence, and
most importantly associated cirrhotic background, altogether
making a HCC hard to cure malignancy. In addition, HCC
is characterized by heterogeneity in terms of genetic diver-
sity, tumor behavior, and patient population [3,4].
In spite of an effort to detect early stage of HCC in patients
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at risk through a surveillance program, a substantial propor-
tion of patients with HCC are still diagnosed at an advanced
stage of the disease when the survival rate is poor [5]. Poten-
tially curative treatments including resection, ablation, and
liver transplantation can be applied only to HCC detected at
an early stage (single nodule  5 cm or 2-3 nodules  3 cm)
[6]. Transarterial chemoembolization (TACE) is regarded as
standard-of-care for multinodular HCC without vascular 
invasion and extrahepatic metastasis [7].
Sorafenib is the first developed molecular targeted agent
in HCC which blocks the Raf/MEK/ERK pathway by 
inhibiting Raf serine/threonine kinase and also inhibiting the
upstream receptor tyrosine kinases that are important in 
angiogenesis, such as vascular endothelial growth factor 
receptor (VEGFR)-2, VEGFR-3, platelet derived growth fac-
tor receptor  and kit [8]. In a global phase III, randomized
trial of 602 patients with advanced HCC, the median overall
survival (OS) was 10.7 months in the sorafenib group com-
pared with 7.9 months in the placebo group (hazard ratio,
0.69; 95% confidence interval, 0.55 to 0.87; p < 0.001). The sur-
vival benefit was preceded by a delay in time to progression
(TTP): 5.5 months for sorafenib versus 2.8 months for control
(p < 0.001) [9]. Another phase III trial conducted in the Asia-
Pacific (AP) area confirmed the survival benefit of sorafenib
in unresectable HCC [10]. Based on these results, sorafenib
was approved as the first systemic drug for patients with 
advanced HCC not amenable to resection, transplantation,
or locoregional treatments [7,8].
Data obtained from well-controlled clinical trials might not
be translated into a real-clinical setting, particularly in HCC
treatment. The efficacy and safety of sorafenib in HCC 
patients with liver dysfunction remain largely unknown, as
only patients of Child-Pugh A were included in the trials.
GIDEON (Global Investigation of Therapeutic Decisions in
HCC and of Its Treatment with Sorafenib) is a prospective,
non-interventional study conducted to fulfil post-approval
commitments to licensing agencies [11]. GIDEON is one of
the largest studies conducted in patients with unresectable
HCC, and the data facilitate broad evaluation of patient sub-
groups. Many subanalyses were therefore planned and per-
formed, with a focus on potentially predictive or prognostic
factors, including Child-Pugh score, Barcelona Clinic Liver
Cancer (BCLC) stage, and etiology.
Herein, we report on real-life experience of sorafenib ther-
apy for HCC in Korea, using a subset of the GIDEON data.
Materials and Methods
1. The design and objectives of GIDEON
GIDEON recruited patients who were candidates for sys-
temic therapy, for whom the decision to treat with sorafenib
was made in real-life practice conditions including patients
with Child-Pugh B liver function. The details of the study 
design have been previously published [12]. The primary 
objective of GIDEON is to evaluate the safety of sorafenib in
patients with unresectable HCC in real-life. The secondary
objectives are to explore drug efficacy in terms of OS, pro-
gression-free survival, TTP, response rate (RR), and disease
control rate (DCR); to determine the duration of therapy 
according to various patient characteristics; to assess meth-
ods of patient evaluation, diagnosis, and follow-up; to assess
comorbidities and their influence on treatment and outcome
in real-life practice rather than a controlled clinical trial set-
ting; and to evaluate the practice pattern of the physicians 
involved in the care of these patients.
2. Patients
Eligible patients were those diagnosed histologically or 
radiographically with HCC, who have a life expectancy of 
> 8 weeks and in whom the decision to treat with sorafenib
was made by their physician. Detailed inclusion criteria are
outlined in the previously published study design report
[11]. Exclusion criteria were those dictated by the manufac-
turer of the drug. Written informed consents were given by
all patients and the study was approved by the individual
institutional review board. More than 3,000 patients were 
recruited from 39 countries of five geographic regions 
between January 2009 and April 2012. A total of 497 patients
were enrolled from 11 sites in Korea during the same period.
Of these, 482 patients were evaluable for safety analyses after
exclusion of 15 patients who did not receive at least one dose
of sorafenib during the study period (n=5) or did not 
undergo at least one assessment for follow-up after initiating
study medication, regardless of previous systemic treatment
(n=10).
3. Data collection and analyses
Paper or electronic case report forms were used to record
data from all enrolled patients at study entry and start of 
sorafenib, then at intervals chosen by the prescribing physi-
cian until death, withdrawal from the study, or loss to fol-
low-up. All adverse events (AEs) were graded according to
the National Cancer Institute Common Terminology Criteria
ver. 3.0 (National Cancer Institute, Bethesda, MD), and their
1244 CANCER  RESEARCH  AND  TREATMENT
Do Young Kim, Sorafenib Treatment of HCC
likely relationship to sorafenib therapy was documented.
HCC assessment was made by computed tomography or
other equivalent radiographical method and was evaluated
using the Response Evaluation Criteria in Solid Tumors 
(RECIST). All efficacy and safety data were summarized
using descriptive statistics.
Results
1. Baseline patient characteristics
The baseline demographic and tumor characteristics of 482
patients evaluable in terms of safety analysis are shown in
Table 1. Male patients predominated (85.5%), and 76.8% of
patients were under 65 years of age (median age, 55.0 years).
The most common underlying etiology was hepatitis B virus
(HBV) infection (81.1%), followed by alcohol use (26.3%).
Most patients were Child-Pugh A class (56.8%), with fewer
Child-Pugh B patients (21.8%). Eastern Cooperative Oncol-
ogy Group (ECOG) performance status was 1 (44.8%) and 
0 (33.8%) in most patients.
All BCLC stages were represented but most patients
(60.8%) were BCLC stage C, while 4.8% of patients were
BCLC stage B, 4.6% stage D, and 0.8% stage A. In terms of
TNM staging, stage III and IV patients accounted for 25.9%
and 52.5% of all patients, respectively, and only a few were
TNM stage I (0.2%) or II (1.9%). Portal vein thrombosis was
observed in 50.4% of patients and extrahepatic spread in
66.0%. Prior locoregional treatment (LRT) was administered
in 68.3% of all patients, with TACE being the most common.
Thus, 60.6% of all patients had undergone prior TACE com-
pared with 14.5%, 8.3%, and 2.1% of patients treated with
prior radiofrequency ablation, hepatic arterial infusional
chemotherapy, or percutaneous ethanol injection, respec-
tively.
2. Sorafenib administration
Data on sorafenib administration are shown in Table 2. 
The mean duration of treatment was 15 weeks (median, 
8.7 weeks). Approximately 67% of patients received the 
approved initial daily dose of 800 mg, while 31.5% received
a half dose (400 mg). Only a few patients received 200 mg or
600 mg as an initial daily dose (0.6% and 0.8%, respectively).
Patients were most frequently treated for 4-8 weeks (22.0%),
followed by  4 weeks (21.4%) and > 28 weeks (12.7%).
Analysis of sorafenib dosing was based on Child-Pugh
class (A or B) (Table 2). The duration of sorafenib adminis-
tration was generally longer in Child-Pugh A than B patients.
Table 1. Baseline patient characteristics
Variable No. (%) (n=482)
Age (yr)
Mean±SD 55.9±10.5
Median 55.0 (
< 65 370 (76.8)
65 to < 75 95 (19.7)
 75 17 (3.5)
Sex
Male 412 (85.5)
Female 70 (14.5)
Etiology of HCCa)
HBV 391 (81.1)
HCV 26 (5.4)
Alcohol 127 (26.3)
Unknown 22 (4.6)
Cirrhosis
Yes 307 (63.7)
No 101 (21.0)
Unknown 74 (15.4)
Child-Pugh class
A 274 (56.8)
B 105 (21.8)
C 6 (1.2)
Unknown 97 (20.1)
BCLC stage
A 4 (0.8)
B 23 (4.8)
C 293 (60.8)
D 22 (4.6)
Unknown 140 (29.0)
TNM stage
I 1 (0.2)
II 9 (1.9)
IIIa 72 (14.9)
IIIb 19 (3.9)
IIIc 34 (7.1)
IV 253 (52.5)
Unknown 94 (19.5)
Portal vein thrombosis 243 (50.4)
Extrahepatic spread 318 (66.0)
ECOG at start of therapy
0 163 (33.8)
1 216 (44.8)
 2 36 (7.5)
Unknown 37 (13.9)
Prior anti-cancer therapy
LRT 329 (68.3)
TACE 292 (60.6)
RFA 70 (14.5)
HAIC 40 (8.3)
PEI 10 (2.1)
SD, standard deviation; HCC, hepatocellular carcinoma;
HBV, hepatitis B virus; HCV, hepatitis C virus; BCLC,
Barcelona Clinic Liver Cancer; ECOG, Eastern Coopera-
tive Oncology Group; LRT, locoregional therapy; TACE,
transarterial chemoembolization; RFA, radiofrequency 
ablation; HAIC, hepatic arterial infusion chemotherapy;
PEI, percutaneous ethanol injection. a)Multiple responses
were possible for etiology of underlying disease and LRT.
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More Child-Pugh A patients received sorafenib for > 8 weeks
compared with Child-Pugh B patients (55.5% vs. 34.3%).
However, some Child-Pugh B patients were treated for
longer periods, and 3.8% of Child-Pugh B patients received
> 28 weeks of sorafenib therapy. Child-Pugh score did not
appear to influence the starting dose of sorafenib; approxi-
mately 70% of patients in both Child-Pugh A and B class 
received the recommended initial daily dose of 800 mg
(69.0% and 69.5%, respectively) and the median daily dose
was slightly lower in Child-Pugh A patients than B patients
(661.5 mg vs. 715.0 mg). The frequency of permanent discon-
tinuation of sorafenib due to AEs was similar between Child-
Pugh A and B patients (29.6% and 32.4%, respectively).
3. Response to sorafenib and treatment outcomes
Response to sorafenib was assessed using intent-to-treat
analysis (ITT) of all patients who received at least one dose
of sorafenib. A total of 490 patients were valid for the ITT set.
According to RECIST criteria, three patients (0.61%) achieved
complete response (CR), while partial response (PR) and sta-
ble disease (SD) were observed in 10 (2.04%) and 131
(26.73%) patients. There were 247 (50.41%) patients who
showed progressive disease (Table 3). The objective RR
(CR+PR) was 2.65% and the DCR, defined as proportion of
patients with the best response rating of documented CR, PR,
or SD maintained for at least 28 days from the first demon-
stration of that rating, was 79 (16.12%). Of 13 patients who
achieved an objective response, the median time to response
was 65 days and the median duration of response was 556
days. The median duration of SD was 68 days.
The median OS and TTP were 8.5 months and 2.5 months,
respectively (Fig. 1). In particular, the median OS and TTP
in Child-Pugh A patients was 10.2 months and 2.5 months.
Of note, the OS and TTP appeared to be longer in patients
whose starting dose was 800 mg rather than 400 mg. The OS
and TTP were 9.3 and 2.8 months in patients with a starting
dose of 800 mg, compared to 7.8 and 2.4 months in those with
400 mg, respectively (Table 4).
4. Safety assessments
At least one treatment-emergent adverse event (TEAE)
was reported for 82.2% of patients (Table 5), and 293 patients
Table 2. Sorafenib administration according to Child-Pugh class
Variable Total (n=482) Child-Pugh A (n=274) Child-Pugh B (n=105)
Duration of treatment (wk)
Mean±SD 14.93±17.36 17.01±19.73 8.55±8.66
Median 8.70 ( 10.05 ( 6.00 (
 4 103 (21.4) 47 (17.2) 35 (33.3)
4-8 106 (22.0) 65 (23.7) 24 (22.9)
8-12 67 (13.9) 37 (13.5) 14 (13.3)
12-16 42 (8.7) 27 (9.9) 8 (7.6)
16-20 36 (7.5) 20 (7.3) 6 (5.7)
20-24 22 (4.6) 16 (5.8) 1 (1.0)
24-28 19 (3.9) 10 (3.6) 3 (2.9)
> 28 61 (12.7) 42 (15.3) 4 (3.8)
Unknown 26 (5.4) 10 (3.6) 10 (9.5)
Average daily dose (mg)
Mean±SD 626.0±177.0 626.8±173.0 640.3±178.2
Median 669.5 ( 661.5 ( 715.0 (
Unknown (n) 52 ( 26 ( 13 (
Initial dose (mg)
200 3 (0.6) 1 (0.4) 1 (1.0)
400 152 (31.5) 83 (30.3) 29 (27.6)
600 4 (0.8) 1 (0.4) 2 (1.9)
800 323 (67.0) 189 (69.0) 73 (69.5)
Permanent discontinuation 127 (26.3) 81 (29.6) 34 (32.4)
of sorafenib due to AE
Values are presented as number (%) unless otherwise indicated. Data for patients with not evaluable Child-Pugh status
(n=97) and Child-Pugh C (n=6) is not included in this table. SD, standard deviation; AE, adverse event.
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(60.8%) experienced drug-related TEAEs. Of these, 16.2% 
patients had grade 3 events and 0.8% of patients had grade
4 events. Overall, 36.9% of patients (n=178) experienced
treatment-emergent serious adverse events (SAEs) and 4.4%
experienced treatment-emergent drug-related SAEs. Sora-
fenib was permanently discontinued as a result of TEAEs in
26.3% of patients.
The incidence of TEAEs was similar between Child-Pugh
A (85.4%) and Child-Pugh B (84.8%) patients (Table 5). How-
ever, the incidence of drug-related TEAEs and that of grade
3 TEAEs was higher in Child-Pugh A than B patients (treat-
ment-emergent drug-related AEs, 66.4% vs. 56.2%; grade 3
TEAEs, 28.5% vs. 18.1%). Treatment-emergent SAEs 
occurred more often in Child-Pugh B than A patients (52.4%
vs. 34.3%). Treatment-emergent drug-related SAEs occurred
in 4.4% of Child-Pugh A and 7.6% of Child-Pugh B patients.
The rates of sorafenib discontinuation due to AEs, regardless
of any causal relationship with sorafenib, was similar in
Child-Pugh A (29.6%) and B patients (32.4%). Treatment
emergent deaths were higher in Child-Pugh B than A 
patients (28.6% vs. 10.9%).
The most commonly reported TEAEs in the overall popu-
Table 3. Response to sorafenib by intent-to-treat analysis
Response No. (n=490) Rate (%) 90% CI (%)
Complete response 3 0.61 0.17-1.57
Partial response 10 2.04 1.11-3.44
Stable diseasea) 131 26.73 23.45-30.22
Progressive disease 247 50.41 46.60-54.22
Not assessable 99 20.20 17.26-23.42
Objective response 13 2.65 1.58-4.19
Disease control rateb) 79 16.12 13.45-19.11
Tumor response was assessed by Response Evaluation Criteria in Solid Tumors (RECIST) ver. 1.0. Denominator for rates
(%) and 90% confidence interval (CI) were based on patient population for analysis. a)Stable disease: patients with best overall
response of stable disease at least 6 weeks after first dose of sorafenib, b)Disease control rate: patients with best response
rating of documented complete response, partial response, or stable disease maintained for at least 28 days from the first
demonstration of that rating. 
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Fig. 1. The median overall survival (OS) (A) and time to progression (TTP) (B) in the entire study population was 8.5 months
and 2.5 months, respectively. The response was estimated based on Response Evaluation Criteria in Solid Tumors ver. 1.0.
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lation included hand-foot skin reaction (32.2%), diarrhea
(22.8%), and abdominal pain (20.1%) (Table 6). Hand-foot
skin reaction (6.0%), bilirubin elevation (5.2%), and throm-
bocytopenia (4.5%) were the most commonly reported grade
3 or 4 AEs in Korea, while the most common grade 4 AEs
were liver dysfunction (1.2%) and bilirubin elevation (0.8%).
The most frequent treatment-emergent drug-related AE was
hand-foot skin reaction (31.7%), followed by diarrhea
(18.0%), rash/desquamation (9.3%), and anorexia (8.1%). The
safety profile of Child-Pugh B patients was generally consis-
tent with the overall safety profile.
Discussion
GIDEON is the largest, prospective, non-interventional
global study to investigate the treatment of patients with 
unresectable HCC in the real world, and reflects the current
practice of participating physicians [12].
Looking at the final global data, a total of 3,371 patients
were enrolled from 39 countries across five different regions
and data on 3,202 patients were available for safety analysis
[13]. In terms of etiology, the frequency of HBV infection was
similar to that of hepatitis C virus infection globally (36.5%
vs. 32.9%). Of all patients, 52% were BCLC stage C, while
20% of patients had BCLC-B. Regarding Child-Pugh class,
sorafenib was prescribed in 20.8% of Child-Pugh B patients,
indicating the real-life pattern of sorafenib use in treatment
Cancer Res Treat. 2016;48(4):1243-1252
Table 4. Overall survival and time to progression according to the starting dose of sorafenib
Sorafenib No. Median OS (mo) 95% CI (mo) Median TTP (mo) 95% CI (mo)
400 mg 154 7.8 5.7-10.9 2.4 2.0-3.0
800 mg 329 9.3 7.3-12.5 2.8 2.2-3.2
OS, overall survival; CI, confidence interval; TTP, time to progression.
Table 5. Overview of safety data by Child-Pugh score
Adverse event summary Total Child-Pugh A Child-Pugh B Child-Pugh C Not evaluable(n=482) (n=274) (n=105) (n=6) (n=97)
TEAE (all grades) 396 (82.2) 234 (85.4) 89 (84.8) 4 (66.7) 69 (71.1)
Treatment-emergent 293 (60.8) 182 (66.4) 59 (56.2) 1 (16.7) 51 (52.6)
drug-related AE (all grades)
Treatment-emergent 178 (36.9) 94 (34.3) 55 (52.4) 4 (66.7) 25 (25.8)
SAE (all grades)
Treatment-emergent 21 (4.4) 12 (4.4) 8 (7.6) 0 ( 1 (1.0)
drug-related SAE (all grades)
TEAE resulting in permanent 127 (26.3) 81 (29.6) 34 (32.4) 1 (16.7) 11 (11.3)
discontinuation of sorafenib
All TEAE with CTCAE grade 3 120 (24.9) 78 (28.5) 19 (18.1) 0 ( 23 (23.7)
All treatment-emergent drug-related 78 (16.2) 49 (17.9) 14 (13.3) 0 ( 15 (15.5)
AE with CTCAE grade 3
All TEAE with CTCAE grade 4 24 (5.0) 10 (3.6) 8 (7.6) 0 ( 6 (6.2)
All treatment-emergent drug-related 4 (0.8) 3 (1.1) 0 ( 0 ( 1 (1.0)
AE with CTCAE grade 4
Values are presented as number (%). Adverse event (AE) was assessed by National Cancer Institute Common Toxicity Criteria
(NCI CTC) ver. 3.0 and worst grade. A serious adverse event (SAE) is defined as any AE occurring at any dose that results
in any of the following outcomes: death; life-threatening; hospitalization or prolongation of existing hospitalization; persistent
or significant disability/incapacity; congenital anomaly/birth defect; medically important event. TEAE, treatment-emergent
adverse event; CTCAE, Common Terminology Criteria for Adverse Events.
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of HCC. One-third of all patients had portal vein thrombosis.
The proportion of patients having undergone previous LRT
was 57.5%. In Korean data (total, 482 patients), the most com-
mon cause of HCC was HBV infection (81.1%). The 
frequency of advanced stage (BCLC-C) (60.8%) tended to be
higher than the global figure, but the proportion of patients
with decreased liver function (Child-Pugh B) (21.8%) was
similar to the global proportion, although unknown was
20.1%. Portal vein thrombosis was more common in Korea
(50.4%), and more patients had been previously treated with
locoregional therapy (68.3%), and 66% of patients had extra-
hepatic spread.
Overall, Korean patients treated with sorafenib had more
advanced diseases and more unfavorable prognosis than 
patients from other countries.
The drug safety profile was consistent with both those of
previously published phase III trials and the final GIDEON
data (Table 5) [9,10,13]; the most common drug-related AEs
were hand foot skin reaction (31.7%) and diarrhea (18%). 
Collectively, the incidence of AEs including SAEs and treat-
Table 6. Incidences of treatment-emergent and treatment-emergent drug-related adverse events (AE)
AEa) Treatment-emergent AEs Treatment-emergent drug-related AEs
Total (n=482) Grade 3 or 4 (n=482) Total (n=482) Grade 3 or 4 (n=482)
Any AE 396 (82.2) 144 (29.9) 293 (60.8) 82 (17.0)
Blood/bone marrow 56 (11.6) 36 (7.4) 40 (8.3) 22 (4.6)
Thrombocytopenia 34 (7.1) 22 (4.5) 27 (5.6) 15 (3.1)
Constitutional symptoms 110 (22.8) 9 (1.9) 37 (7.7) 2 (0.4)
Fatigue 50 (10.4) 4 (0.8) 28 (5.8) 2 (0.4)
Fever 41 (8.5) 1 (0.2) 7 (1.5) -
Dermatology/Skin 202 (41.9) 36 (7.5) 190 (39.4) 34 (7.1)
Alopecia 32 (6.6) - 31 (6.4) -
Hand-foot skin reaction 155 (32.2) 29 (6.0) 153 (31.7) 29 (6.0)
Rash/Desquamation 53 (11.0) 5 (1.0) 45 (9.3) 5 (1.0)
Gastrointestinal 236 (49.0) 46 (9.5) 153 (31.7) 16 (3.3)
Anorexia 69 (14.3) 8 (1.7) 39 (8.1) 3 (0.6)
Ascites 40 (8.3) 18 (3.7) - -
Constipation 24 (5.0) - 6 (1.2) -
Diarrhea 110 (22.8) 10 (2.1) 87 (18.0) 9 (1.9)
Distension 25 (5.2) 3 (0.6) 1 (0.2) -
Heartburn 29 (6.0) - 15 (3.1) -
Mucositis in oral cavity 25 (5.2) 1 (0.2) 19 (3.9) 1 (0.2)
Nausea 56 (11.6) 2 (0.4) 30 (6.2) 1 (0.2)
Vomiting 29 (6.0) 1 (0.2) 15 (3.1) 1 (0.2)
Hemorrhage/Bleeding 63 (13.1) 21 (4.3) 19 (3.9) 2 (0.4)
Hepatobiliary/Pancreas 53 (11.0) 16 (3.4) 4 (0.8) 2 (0.4)
Liver dysfunction 40 (8.3) 9 (1.8) 4 (0.8) 2 (0.4)
Infection 32 (6.6) 11 (2.3) 3 (0.6) 1 (0.2)
Lymphatics (edema) 26 (5.4) 1 (0.2) 2 (0.4) -
Metabolic/Laboratory 68 (14.1) 49 (10.2) 10 (2.1) 7 (1.4)
Bilirubin elevation 36 (7.5) 25 (5.2) 2 (0.4) 2 (0.4)
Neurology 60 (12.4) 18 (3.7) 14 (2.9) 1 (0.2)
Encephalopathy 26 (5.4) 13 (2.7) 3 (0.6) 1 (0.2)
Pain 161 (33.4) 31 (6.4) - 37 (7.7)
Abdominal pain 97 (20.1) 18 (3.7) - 17 (3.5)
Pulmonary/Upper respiratory 80 (16.6) 9 (1.9) - 12 (2.5)
Cough 26 (5.4) - - -
Dyspnea 31 (6.4) 8 (1.7) - 1 (0.2)
Values are presented as number (%). a)Assessed by National Cancer Institute Common Terminology Criteria for Adverse
Events (NCI CTCAE) ver. 3.0.
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ment-emergent AEs was similar in Child-Pugh A and B 
patients, and in particular, Child-Pugh B did not appear to
increase drug-related AEs or the rate of permanent sorafenib
discontinuation, compared to Child-Pugh A (Table 4). A pos-
sible explanation for this is the consistent pharmacokinetics
(PK) of sorafenib in Child-Pugh A and B patients. The PK
data indicate that the maximal concentration and the geo-
metric means of area under curve at steady state were not
significantly different between Child-Pugh A and B patients.
This characteristic of PK might make Child-Pugh score less
influential on the safety of sorafenib treatment [14].
Although a non-interventional study cannot thoroughly
evaluate drug efficacy, and data interpretation must be done
with caution, we sought to determine the efficacy of soraf-
enib in Korean HCC patients in a real life practice setting.
The median OS was 8.5 months, and thus seems superior to
that observed in the AP phase III study, even though more
BCLC-B patients were included in GIDEON (11.2% vs. 4.7%)
[10]. However, we also have to consider that the majority of
patients in the AP study were of Child-Pugh A. If only Child-
Pugh A patients are considered, the median OS is 13.6 and
10.2 months in global and Korean data, respectively, and
these are superior to the AP study and seem comparable
even to SHARP (10.7 months). In addition, the median TTP
was 2.5 months in Korean patients with Child-Pugh A, also
comparable to that of the AP trial (Table 7). Consequently,
our result has confirmed the benefit of sorafenib in Korean
patients with HCC, showing longer OS compared to the AP
sorafenib study. Another finding from this study was the
comparison of efficacy between different starting dose of 
sorafenib (reduced vs. full). Due to various reasons including
concern of AE and old patient’s age, starting dose of 
sorafenib is occasionally reduced to half (400 mg) or to three-
fourths (600 mg). Despite several selection biases regarding
comparison of efficacy between different starting doses and
no analytical statistics were performed, OS in patients who
received 800 mg appeared to be longer (median survival, 9.3
months) than that of patients on 400 mg (7.8 months). Such
a result is in agreement with that from the global GIDEON
trial [15]. However, further studies are necessary to clarify
whether a full dose of sorafenib can result in longer survival
or better baseline patient characteristics, leading physicians
to start and maintain full dose of sorafenib.
Overall, the survival benefit in the Korean GIDEON study
was less than that observed globally (median OS, 10.8
months globally vs. 8.5 months in Korea), probably because
Korean patients presented with more advanced disease 
represented by high frequency of BCLC-C, Child-Pugh B,
and involvement of portal vein as well as predominant 
etiology of CHB.
Several international guidelines suggest the use of 
sorafenib in treatment of Child-Pugh B patients with 
advanced HCC, although most enrolled patients in random-
ized trials were Child-Pugh A; such patients have no other
treatment option because of poor liver function [8,16]. 
Sorafenib has been used in treatment of Child-Pugh B 
patients in Korea, and was prescribed for 21.8% of all 
patients. The initial dose and average daily dose in Child-
Pugh B patients were similar to those administered to Child-
Pugh A patients, and the extent of permanent treatment
discontinuation triggered by development of AEs was simi-
lar in both groups. Although treatment duration tended to
be shorter in Child-Pugh B patients, the most common rea-
son for treatment discontinuation except disease progression
was patient’s own decision including financial reason. AE
was the second most common reason; however, the inci-
dence is not different between Child-Pugh A and B. In addi-
tion, neither the safety profile nor the incidence of AEs
differed between Child-Pugh A and B patients. Accordingly,
Child-Pugh score did not influence sorafenib dosing strategy
and we found no evidence that AEs associated with 
sorafenib were more prevalent in patients with decreased
liver function. Nevertheless, more prospective evidence is
needed in terms of effectiveness and safety of sorafenib treat-
ment in advanced HCC with Child-Pugh B. The interpreta-
tion of finding that the safety profile of sorafenib by the
Table 7. Survival benefit of sorafenib in studies
Variable GIDEON global data (n=3,202) GIDEON Korean data (n=482) SHARP (n=299) AP (n=150)
Child-Pugh A 1,968 (61.5) 279 (56.8) 284 (95) 146 (97.3)
Survival (overall, mo) 10.8 ( 8.5 ( 10.7 ( 6.5 (
Child-Pugh A 13.6 ( 10.2 ( - -
Time to progression (overall, mo) 4.8a) ( 2.5a) ( 5.5b) ( 2.8b) (
Child-Pugh A 4.7a) ( 2.5a) ( - -
Values are presented as number (%). GIDEON, Global Investigation of Therapeutic Decisions in hepatocellular carcinoma
and of Its Treatment with Sorafenib; AP, Asian-Pacific. a)Assessed by Response Evaluation Criteria in Solid Tumors (RECIST)
ver. 1.0, b)Assessed by RECIST. 
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